Literature DB >> 10364648

The cost of dementia in Denmark: the Odense Study.

C Kronborg Andersen1, J Søgaard, E Hansen, A Kragh-Sørensen, L Hastrup, J Andersen, K Andersen, A Lolk, H Nielsen, P Kragh-Sørensen.   

Abstract

In a population-based study of dementia, the cost of care for 245 demented elderly and 490 controls matched by age and gender was estimated. Dementia of Alzheimer's type was diagnosed according to the NINCDS-ADRDA criteria, and vascular dementia and other types of dementia were diagnosed according to the DSM-IIIR criteria. Severity of dementia was determined by the Clinical Dementia Rating scale. The annual cost of medical care, domestic care, home help, nursing home and special equipment for nondemented patients was DKK 22,000 per person while the cost for very mildly, mildly, moderately and severely demented patients was DKK 49,000, DKK 93,000, DKK 138,000 and DKK 206,000, respectively. Except for very mild dementia the cost did not differ between elderly who suffer from Alzheimer's disease and those with other types of dementia. The net cost of dementia is the difference in cost between those with dementia and the matched controls and amounts on average to DKK 77,000 per person per year. However, priority setting cannot be based on the cost of dementia per se, but only on the cost of a specific dementia intervention compared to its health benefit.

Entities:  

Mesh:

Year:  1999        PMID: 10364648     DOI: 10.1159/000017135

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  15 in total

Review 1.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Alzheimer's disease: the strength of association of costs with different measures of disease severity.

Authors:  J Mauskopf; J Racketa; E Sherrill
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

3.  Relationship between global severity of patients with Alzheimer's disease and costs of care in Spain; results from the co-dependence study in Spain.

Authors:  J Darbà; L Kaskens; L Lacey
Journal:  Eur J Health Econ       Date:  2014-10-28

Review 4.  A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease.

Authors:  Joanna Kirby; Colin Green; Emma Loveman; Andrew Clegg; Joanna Picot; Andrea Takeda; Elizabeth Payne
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 6.  Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.

Authors:  Linus Jönsson
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Dementia and out-of-pocket spending on health care services.

Authors:  Adeline Delavande; Michael D Hurd; Paco Martorell; Kenneth M Langa
Journal:  Alzheimers Dement       Date:  2012-11-13       Impact factor: 21.566

8.  Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.

Authors:  Roy W Jones; Paul McCrone; Chantal Guilhaume
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  The cost of dementia in Europe: a review of the evidence, and methodological considerations.

Authors:  Linus Jönsson; Anders Wimo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Excess costs of dementia disorders and the role of age and gender - an analysis of German health and long-term care insurance claims data.

Authors:  Larissa Schwarzkopf; Petra Menn; Reiner Leidl; Sonja Wunder; Hilmar Mehlig; Peter Marx; Elmar Graessel; Rolf Holle
Journal:  BMC Health Serv Res       Date:  2012-06-19       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.